Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

Eli Lilly has asked to intervene in litigation between a compounding pharmacy trade group and the FDA over the agency’s ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Eli Lilly moves to defend FDA's tirzepatide shortage resolution amid criticism over supply issues and compounding pharmacy ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

The US FDAd re-issued a decision first made in October that a shortage of the diabetes/weight-loss medication tirzepatide is ...

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity and prediabetes.

FILE - Zepbound injection pen (Photographer: Shelby Knowles/Bloomberg via Getty Images) According to Eli Lilly, after one ... are versions of a drug called tirzepatide. Zepbound, Mounjaro ...

FILE - Zepbound injection pen (Photographer: Shelby Knowles/Bloomberg via Getty Images) According to Eli Lilly, after one year ... Mounjaro and Zepbound are versions of a drug called tirzepatide.